While previous studies have demonstrated that MSI1 knockdown (de Araujo et al., 2016; Lin et al., 2018; Troschel et al., 2021b; Falke et al., 2022) or dual MSI1/MSI2 targeting (Troschel et al., 2020; Löblein et al., 2021) sensitize solid malignancies to radiotherapy, data on the radiation relevance of MSI2 remain rare (Qu et al., 2024) and neither approach has previously been tested in hematologic malignancies. This evidence concerns the gene MSI2 and hematologic disorder.